Aneeka Chaudhry1, Edyta Pawelczyk2,
Eric Gold1, Bobbi K. Lewis1, Melissa Brown1,
Arun Balakumaran3, Joseph A. Frank1,4
1Clinical Center, NIH, Bethesda, MD,
United States; 2Federal Drug Administration, Bethesda, MD, United
States; 3National Institute of Dental and Craniofacial Research,
NIH, Bethesda, MD, United States; 4National Institute of
Biomedical Imaging and Bioengineering, NIH, Bethesda, MD, United States
In-vivo
loss of implanted or infused cells is detrimental to stem cell therapies, as
it undermines cell homing and therapeutic efficacy. This study aims to improve the homing and
survival of FePro labeled bone marrow stromal cells via incubation with a
cocktail of pro-survival and growth factors.